Harrow (NASDAQ:HROW) Stock Price Up 7.7% – Still a Buy?

Harrow, Inc. (NASDAQ:HROW) was up 7.7% during trading on Thursday . The stock traded as high as $36.24 and last traded at $36.15. Approximately 295,975 shares traded hands during mid-day trading, a decline of 41% from the average daily volume of 497,813 shares. The stock had previously closed at $33.55.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on HROW shares. B. Riley reduced their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. Craig Hallum increased their price target on Harrow from $45.00 to $65.00 and gave the company a “buy” rating in a report on Friday, October 4th. Finally, Lake Street Capital increased their price target on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Friday, October 4th.

Harrow Stock Performance

The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The stock has a market cap of $1.29 billion, a PE ratio of -38.41 and a beta of 0.69. The firm’s 50-day moving average is $41.15 and its 200 day moving average is $37.54.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quest Partners LLC purchased a new stake in Harrow in the 3rd quarter valued at approximately $29,000. nVerses Capital LLC purchased a new position in Harrow during the second quarter worth about $33,000. Allspring Global Investments Holdings LLC boosted its stake in Harrow by 2,730.7% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after buying an additional 2,048 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Harrow by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company’s stock valued at $57,000 after buying an additional 227 shares during the period. Finally, Hills Bank & Trust Co acquired a new position in shares of Harrow during the 3rd quarter valued at about $107,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.